NovaBay Pharmaceuticals (NBY) Competitors $0.53 +0.03 (+5.12%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrends NBY vs. SNSE, TSBX, JAGX, PHXM, INDP, CLRB, CYCN, MYNZ, EGRX, and BCDAShould you be buying NovaBay Pharmaceuticals stock or one of its competitors? The main competitors of NovaBay Pharmaceuticals include Sensei Biotherapeutics (SNSE), Turnstone Biologics (TSBX), Jaguar Health (JAGX), PHAXIAM Therapeutics (PHXM), Indaptus Therapeutics (INDP), Cellectar Biosciences (CLRB), Cyclerion Therapeutics (CYCN), Mainz Biomed (MYNZ), Eagle Pharmaceuticals (EGRX), and BioCardia (BCDA). These companies are all part of the "pharmaceutical products" industry. NovaBay Pharmaceuticals vs. Sensei Biotherapeutics Turnstone Biologics Jaguar Health PHAXIAM Therapeutics Indaptus Therapeutics Cellectar Biosciences Cyclerion Therapeutics Mainz Biomed Eagle Pharmaceuticals BioCardia NovaBay Pharmaceuticals (NYSE:NBY) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, community ranking, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings. Do institutionals and insiders believe in NBY or SNSE? 23.3% of NovaBay Pharmaceuticals shares are held by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are held by institutional investors. 0.1% of NovaBay Pharmaceuticals shares are held by insiders. Comparatively, 22.0% of Sensei Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media favor NBY or SNSE? In the previous week, NovaBay Pharmaceuticals had 1 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 1 mentions for NovaBay Pharmaceuticals and 0 mentions for Sensei Biotherapeutics. NovaBay Pharmaceuticals' average media sentiment score of 0.00 equaled Sensei Biotherapeutics'average media sentiment score. Company Overall Sentiment NovaBay Pharmaceuticals Neutral Sensei Biotherapeutics Neutral Does the MarketBeat Community believe in NBY or SNSE? Sensei Biotherapeutics received 26 more outperform votes than NovaBay Pharmaceuticals when rated by MarketBeat users. Likewise, 79.41% of users gave Sensei Biotherapeutics an outperform vote while only 2.04% of users gave NovaBay Pharmaceuticals an outperform vote. CompanyUnderperformOutperformNovaBay PharmaceuticalsOutperform Votes12.04%Underperform Votes4897.96% Sensei BiotherapeuticsOutperform Votes2779.41% Underperform Votes720.59% Do analysts prefer NBY or SNSE? NovaBay Pharmaceuticals presently has a consensus price target of $0.85, indicating a potential upside of 60.41%. Sensei Biotherapeutics has a consensus price target of $4.33, indicating a potential upside of 863.18%. Given Sensei Biotherapeutics' higher possible upside, analysts plainly believe Sensei Biotherapeutics is more favorable than NovaBay Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NovaBay Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Sensei Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, NBY or SNSE? NovaBay Pharmaceuticals has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, Sensei Biotherapeutics has a beta of 0.16, indicating that its share price is 84% less volatile than the S&P 500. Which has higher valuation and earnings, NBY or SNSE? NovaBay Pharmaceuticals has higher revenue and earnings than Sensei Biotherapeutics. Sensei Biotherapeutics is trading at a lower price-to-earnings ratio than NovaBay Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovaBay Pharmaceuticals$13.84M0.19-$9.64M-$53.72-0.01Sensei BiotherapeuticsN/AN/A-$34.10M-$1.19-0.38 Is NBY or SNSE more profitable? Sensei Biotherapeutics has a net margin of 0.00% compared to NovaBay Pharmaceuticals' net margin of -102.72%. Sensei Biotherapeutics' return on equity of -53.86% beat NovaBay Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets NovaBay Pharmaceuticals-102.72% -7,293.78% -158.41% Sensei Biotherapeutics N/A -53.86%-46.91% SummarySensei Biotherapeutics beats NovaBay Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Ad Weiss RatingsNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …Find out details on these three critical Nvidia partners immediately. Get NovaBay Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NBY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBY vs. The Competition Export to ExcelMetricNovaBay PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$2.60M$6.57B$5.14B$19.19BDividend YieldN/A3.00%5.09%3.62%P/E Ratio-0.0110.5990.0541.30Price / Sales0.19195.801,117.1417.58Price / CashN/A57.1643.0421.28Price / Book0.125.094.785.32Net Income-$9.64M$151.83M$120.31M$989.88M7 Day Performance-7.83%-2.13%-1.92%-3.54%1 Month Performance-26.38%-3.10%11.51%-3.68%1 Year Performance-93.40%11.54%30.61%12.14% NovaBay Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBYNovaBay Pharmaceuticals1.4551 of 5 stars$0.53+5.1%$0.85+60.4%-93.4%$2.60M$13.84M-0.0130Analyst ForecastNews CoverageGap UpSNSESensei Biotherapeutics4.077 of 5 stars$0.44-0.6%$4.33+890.7%-28.6%$11.00MN/A-0.3740Positive NewsGap DownTSBXTurnstone Biologics2.8506 of 5 stars$0.47-1.9%$2.13+351.2%-80.2%$10.89M$19.31M-0.1582Positive NewsGap DownJAGXJaguar Health0.2602 of 5 stars$0.91-6.0%N/A-89.9%$10.75M$9.76M0.0050News CoverageGap UpPHXMPHAXIAM TherapeuticsN/A$3.10-0.6%N/AN/A$10.58M$32.66M0.0049INDPIndaptus Therapeutics2.8722 of 5 stars$1.02+2.0%$8.50+733.3%-49.6%$10.40MN/A-0.586CLRBCellectar Biosciences1.798 of 5 stars$0.25-4.7%$17.67+7,026.5%-91.1%$10.23MN/A-0.1510Analyst ForecastGap UpHigh Trading VolumeCYCNCyclerion Therapeutics0.6403 of 5 stars$3.73+8.7%N/A-22.2%$10.11M$194,000.000.0030Gap DownMYNZMainz Biomed2.5037 of 5 stars$5.01-6.5%$120.00+2,295.2%-85.7%$10.03M$917,203.00-0.0730News CoverageGap UpEGRXEagle Pharmaceuticals1.0016 of 5 stars$0.75+36.4%N/A-89.0%$9.74M$257.55M0.00134Gap UpBCDABioCardia3.3081 of 5 stars$2.08flat$25.00+1,101.9%-79.8%$9.54M$71,000.00-0.5016Analyst ForecastShort Interest ↓Positive NewsGap Up Related Companies and Tools Related Companies SNSE Alternatives TSBX Alternatives JAGX Alternatives PHXM Alternatives INDP Alternatives CLRB Alternatives CYCN Alternatives MYNZ Alternatives EGRX Alternatives BCDA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:NBY) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovaBay Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NovaBay Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NBY Stock Alerts